Workflow
胶原蛋白系列
icon
Search documents
重大资产重组!A股公司公告:不停牌!
券商中国· 2025-09-27 05:21
Core Viewpoint - The A-share market is witnessing a surge in major asset restructuring activities, with significant transactions announced by companies like Dongxing Medical and Fuda Alloy, indicating a revitalization of the M&A landscape following regulatory changes [2][5][9]. Group 1: Dongxing Medical - Dongxing Medical announced plans to acquire 90% of Wuhan Yijiaobao Biological Materials Co., Ltd. for cash, which is expected to constitute a major asset restructuring [2][3]. - The acquisition aligns with Dongxing Medical's strategic business development needs and aims to enhance its capabilities in the surgical medical device sector, particularly in synthetic biology [5][6]. - The transaction is still in the preliminary planning stage, with a share purchase intention agreement signed, but final terms are yet to be negotiated [5][6]. Group 2: Fuda Alloy - Fuda Alloy plans to acquire 52.61% of Zhejiang Guangda Electronic Technology Co., Ltd. for 352 million yuan, which will make it the controlling shareholder [9][10]. - The acquisition is part of Fuda Alloy's strategy to diversify its product offerings in the electronic materials sector, particularly in electronic paste products [9][10]. - Guangda Electronic has shown strong revenue growth, with projected revenues of 1.65 billion yuan in 2023 and 2.68 billion yuan in 2024, indicating a promising outlook for the acquired business [10].
301290,重大资产重组!
证券时报· 2025-09-26 12:54
以下文章来源于e公司 ,作者证券时报 吴志 e公司 . e公司,证券时报旗下专注上市公司新媒体产品,立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯,针对可能影响上市公司股价的 主题概念、行业事件及时采访二次解读,从投资者需求出发,直播上市公司有价值的活动、会议。 东星医疗拟收购武汉医佳宝90%股权。 9月26日,东星医疗(301290)公告,拟以支付现金方式购买武汉医佳宝生物材料有限公司(以下简称"武汉医佳宝"或"标的公司")90%的股权。此次交易如能 顺利实施,武汉医佳宝将成为东星医疗的控股子公司。 根据公告,此次收购基于公司业务发展战略的需要。 具体来看,东星医疗拟以支付现金的方式,收购武汉医佳宝90%的股权。若本次交易能顺利实施完成,公司将持有武汉医佳宝90%的股权。 目前,此次交易尚处于初步筹划阶段。2025年9月26日,东星医疗已经与武汉医佳宝全体股东签订了《股权收购意向协议》,但最终收购股权比例、交易对方 及交易价格尚需交易各方进一步协商后确定。 东星医疗表示,根据初步研究和测算,本次交易预计构成《上市公司重大资产重组管理办法》规定的重大资产重组。本次交易不会导致上市公司控股 ...